Abstract Background The 2021 Canadian Cardiovascular Society guidelines recommend
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor therapy in patients with …

Background Evolocumab is a monoclonal antibody that inhibits proprotein convertase
subtilisin–kexin type 9 (PCSK9) and lowers low-density lipoprotein (LDL) cholesterol levels …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a circulating enzyme of hepatic
origin that plays a key role in LDL receptor turnover. Genetic studies have confirmed that …

Introduction PCSK9 inhibitors (PCSK9i) significantly decrease LDL cholesterol (LDL-C),
either as monotherapy or in addition to the maximally tolerated dose of statin and/or …

Background Two decades ago all statins demonstrated effective triglyceride (TG) reductions
although mainly in hypertriglyceridemic (HTG) patients. The studies supported increased …

BACKGROUND: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a
new class of cholesterol-lowering medications that provide significant reductions in lipids but …

The discovery of proprotein convertase subtilisin kexin-type 9 (PCSK9) and the development
of inhibitors of PCSK9 function appear to mark an epochal advance in clinical lipidology …

Background Familial hypercholesterolemia is characterized by high levels of low-density
lipoprotein cholesterol (LDL-C), and causes of familial hypercholesterolemia include …

Background We sought to examine the efficacy and safety of 2 PCSK9 (proprotein
convertase subtilisin/kexin type 9) inhibitors: alirocumab and evolocumab. Methods and …

Cholesterol carried in low-density lipoprotein cholesterol (LDL-C) and other apolipoprotein
B-containing lipoproteins plays a causal role in atherogenesis, 1–3 and, accordingly, is a …